HIV, Gilead and patent infringement
But just seven years ago, and despite living with HIV for nearly half his life, Duffy was remarkably healthy, working in ...
Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...
Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells ...
Here are some of the findings from UNAIDS' new report on HIV and human rights, and what they could mean for the fight against ...
Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was ...
Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...
Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other ...
The government provides HIV medicines free of charge. Yet in one Indigenous territory, cases and deaths are increasing at an ...
Memphis ranked second in the country for new HIV infections among metropolitan areas in the United States, according to the ...
Every week, 4000 young women contract HIV. Discover hidden barriers to prevention and innovative solutions that can change ...
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...